Pre-Exposure Prophylaxis

In comparison with a potential generic version of tenofovir disoproxil fumarateemtricitabine, or F/TDF, the safety of tenofovir alafenamideemtricitabine, or F/TAF, is worth no more than $370 per person per year among men who have sex with men, according to findings from a cost-effectiveness study presented CROI and published simultaneously in Annals of Internal Medicine.

One-third of pre-exposure prophylaxis, or PrEP, in Kenya and Uganda drug concentrations consistent with poor adherence suggesting a need for new approaches and long-acting formulations, according to a study published in Lancet HIV.

More than half of people with commercial insurance who began pre-exposure prophylaxis, or PrEP, persisted with it for 12 months, compared with a third of those with Medicaid, according to findings published in Clinical Infectious Diseases.

Almost one-quarter of patients who initiate pre-exposure prophylaxis, or PrEP, for HIV prevention have at least one STI, and nearly three-quarters of those who continue to use it are diagnosed with chlamydia, gonorrhea or syphilis within 1 year of using it, according to results from a systematic review and meta-analysis published in JAMA Network Open.

PCPs play a major role in ending the HIV epidemic, according to a special communication published recently in JAMA Internal Medicine.

Distributing free HIV self-tests may be an effective way to increase testing frequency among men who have sex with men, according to results from a randomized clinical trial published in JAMA Internal Medicine.

The FDA’s approval of Talicia for Helicobacter pylori infection, which is associated with up to a six-fold increased risk for gastric cancer, was among the top stories in infectious disease last week.

The United States government filed a patent infringement lawsuit against Gilead Sciences in federal district court, accusing the drug maker of “willfully and deliberatively” infringing on HHS patents for pre-exposure prophylaxis, or PrEP, for HIV prevention.

Judith Feinberg, MD, from West Virginia University School of Medicine, spoke with Healio about important FDA approvals in HIV, the burden of drug resistance, threats to HIV control and the future of HIV treatment.

The FDA’s approval of a second HIV pre-exposure prophylaxis option and a Q&A about antiretroviral stewardship in inpatient practice were two of the most popular infectious disease stories last week.